Loading...
•
Sep 30, 2024
Kiniksa Q3 2024 Earnings Report
Reported third quarter financial results and portfolio execution.
Key Takeaways
Kiniksa Pharmaceuticals reported strong ARCALYST growth, driven by consistent execution and strategic investments. The company expects to remain cash flow positive on an annual basis while investing in commercialization and pipeline advancement.
ARCALYST Q3 2024 net product revenue reached $112.2 million, a 73% year-over-year increase.
ARCALYST 2024 expected net product revenue increased to $410 - $420 million.
Launched Life DisRPted ™ disease awareness campaign for recurrent pericarditis.
Kiniksa expects to remain cash flow positive on an annual basis.
Revenue by Segment
Forward Guidance
Kiniksa anticipates continued growth and financial stability while investing in its pipeline.
Positive Outlook
- ARCALYST net sales are expected to increase to between $410 and $420 million for 2024.
- Company expects to remain cash flow positive on an annual basis.
- Continued investment in commercialization.
- Continued investment in pipeline advancement.
- Enrolling and dosing patients in the Phase 2b clinical trial of abiprubart in Sjögren’s Disease.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...